Getinge AB

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000202624
SEK
210.70
-1.1 (-0.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

300.02 k

Shareholding (Jun 2020)

FII

0.32%

Held by 1 FIIs

DII

99.68%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Positive results in Jun 25

  • RAW MATERIAL COST(Y) Fallen by -1.07% (YoY)
  • NET PROFIT(9M) Higher at SEK 2,174.49 MM
  • DEBTORS TURNOVER RATIO(HY) Highest at 5.08%
2

With ROE of 7.77%, it has a expensive valuation with a 1.97 Price to Book Value

3

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
4

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 55,837 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.09%

stock-summary
Debt Equity

0.26

stock-summary
Return on Equity

9.55%

stock-summary
Price to Book

1.91

Revenue and Profits:
Net Sales:
8,238 Million
(Quarterly Results - Jun 2025)
Net Profit:
527 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.93%
0%
2.93%
6 Months
15.07%
0%
15.07%
1 Year
25.27%
0%
25.27%
2 Years
-7.06%
0%
-7.06%
3 Years
-15.92%
0%
-15.92%
4 Years
-43.78%
0%
-43.78%
5 Years
15.77%
0%
15.77%

Getinge AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.99%
EBIT Growth (5y)
-1.50%
EBIT to Interest (avg)
17.04
Debt to EBITDA (avg)
0.36
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.85
Tax Ratio
27.86%
Dividend Payout Ratio
76.49%
Pledged Shares
0
Institutional Holding
0.32%
ROCE (avg)
15.39%
ROE (avg)
10.58%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
1.97
EV to EBIT
14.59
EV to EBITDA
9.77
EV to Capital Employed
1.75
EV to Sales
1.83
PEG Ratio
NA
Dividend Yield
2.06%
ROCE (Latest)
12.02%
ROE (Latest)
7.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2020stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -0.81% vs 15.73% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 2.73% vs 137.50% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,238.00",
          "val2": "8,305.00",
          "chgp": "-0.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,506.00",
          "val2": "1,399.00",
          "chgp": "7.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "147.00",
          "val2": "130.00",
          "chgp": "13.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.00",
          "val2": "-92.00",
          "chgp": "70.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "527.00",
          "val2": "513.00",
          "chgp": "2.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "120.20%",
          "val2": "109.10%",
          "chgp": "1.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.21% vs 12.49% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -31.88% vs -3.50% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "34,759.00",
          "val2": "31,827.00",
          "chgp": "9.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6,187.00",
          "val2": "5,907.00",
          "chgp": "4.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "500.00",
          "val2": "493.00",
          "chgp": "1.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,717.00",
          "val2": "105.00",
          "chgp": "-1,735.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,654.00",
          "val2": "2,428.00",
          "chgp": "-31.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "117.60%",
          "val2": "119.80%",
          "chgp": "-0.22%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
8,238.00
8,305.00
-0.81%
Operating Profit (PBDIT) excl Other Income
1,506.00
1,399.00
7.65%
Interest
147.00
130.00
13.08%
Exceptional Items
-27.00
-92.00
70.65%
Consolidate Net Profit
527.00
513.00
2.73%
Operating Profit Margin (Excl OI)
120.20%
109.10%
1.11%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -0.81% vs 15.73% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 2.73% vs 137.50% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
34,759.00
31,827.00
9.21%
Operating Profit (PBDIT) excl Other Income
6,187.00
5,907.00
4.74%
Interest
500.00
493.00
1.42%
Exceptional Items
-1,717.00
105.00
-1,735.24%
Consolidate Net Profit
1,654.00
2,428.00
-31.88%
Operating Profit Margin (Excl OI)
117.60%
119.80%
-0.22%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 9.21% vs 12.49% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -31.88% vs -3.50% in Dec 2023

stock-summaryCompany CV
About Getinge AB stock-summary
stock-summary
Getinge AB
Pharmaceuticals & Biotechnology
Getinge AB is a Sweden-based company active in the healthcare sector. It provides products and services for intensive care units, sterilization centers, elderly care and companies and institutions active in the life sciences area. Its operations are divided into three business areas: The Medical Systems business area offers equipment for surgical disciplines, cardiology and intensive care; the Extended Care business area offers products and services geared toward the hospital and elderly care markets, including solutions for preventing the risk of pressure ulcers and deep vein thrombosis, and the Infection Control business area features systems for preventing the occurrence and spread of infection. Its products comprise disinfectors, sterilizers, including low temperature sterilization solutions, information technology (IT) solutions, as well as advice, training and technical support. The Company's products are sold under the Getinge, Lancer, ArjoHuntleigh and MAQUET brands.
Company Coordinates stock-summary
Company Details
Ekebergsvagen 26,, P.O. Box 69 GOETEBORG None : 305 75
stock-summary
Tel: 46 3 515550046 10 3350043
stock-summary
Registrar Details